Scott Williams

Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.

Joseph Sia, Jim Hagekyriakou, Ioana Chindris, Hassan Albarakati, Trevor Leong, Ramona Schlenker, Simon P Keam, Scott G Williams, Paul J Neeson, Ricky W Johnstone, Nicole M Haynes

Journal article  |  2021  |  Int J Radiat Oncol Biol Phys

PURPOSE: We examined how radiation dose per fraction (DPF) and total dose, as represented by biological effective dose (BED), can ..

Prostate cancer.

Shahneen Sandhu, Caroline M Moore, Edmund Chiong, Himisha Beltran, Robert G Bristow, Scott G Williams

Journal article  |  2021  |  Lancet

The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic l..

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin M Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, et al.

Journal article  |  2021  |  EUROPEAN UROLOGY

Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than me..

'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)

Dickon Hayne, Jeremy Grummet, David Espinoza, Steve P McCombie, Venu Chalasani, Kate S Ford, Mark Frydenberg, Peter Gilling, Barbara Gordon, Cynthia Hawks, Alex Konstantatos, Andrew J Martin, Anthony Nixon, Colin O'Brien, Manish Patel, Shomik Sengupta, Shekib Shahbaz, Shalini Subramaniam, Scott Williams, Henry H Woo, et al.

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVE: To determine whether the addition of inhaled methoxyflurane to periprostatic infiltration of local anaesthetic (PILA) d..

Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression

Stefano Mangiola, Patrick McCoy, Martin Modrak, Fernando Souza-Fonseca-Guimaraes, Daniel Blashki, Ryan Stuchbery, Simon P Keam, Michael Kerger, Ken Chow, Chayanica Nasa, Melanie Le Page, Natalie Lister, Simon Monard, Justin Peters, Phil Dundee, Scott G Williams, Anthony J Costello, Paul J Neeson, Bhupinder Pal, Nicholas D Huntington, et al.

Journal article  |  2021  |  BMC CANCER

BACKGROUND: Prostate cancer is caused by genomic aberrations in normal epithelial cells, however clinical translation of findings ..

Ga-68-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer

Amy Davies, Marcus Foo, Chun Loo Gan, John Kourambas, Nicholas Redgrave, Scott Donnellan, Sree Appu, Scott Williams, Andrew Coleman, Eva Segelov, Jason Bradley, Geoffrey Soo, Shakher Ramdave, Edmond M Kwan, Arun A Azad

Journal article  |  2021  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

OBJECTIVE: PSMA PET/CT has demonstrated superior sensitivity over conventional imaging in the detection of local and distant recur..

UpFrontPSMA: a randomized phase 2 study of sequential Lu-177-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Sandhu, Ian D Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman, Arun A Azad

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVE: To assess the activity and safety of sequential lutetium-177 (177 Lu)-PSMA-617 and docetaxel vs docetaxel on a backgrou..

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

Rafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, Jackie Yim, Scott Williams, Roslyn J Francis, Mark Frydenberg, Nathan Lawrentschuk, Declan G Murphy, Richard De Abreu Lourenco

Journal article  |  2021  |  EUROPEAN UROLOGY

BACKGROUND: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-177-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, et al.

Journal article  |  2021  |  LANCET

BACKGROUND: Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prosta..